Digital Transformation And Precision Medicine Will Drive RNA Therapeutics
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 15 Analysts
Published
05 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$32.52
70.8% undervalued intrinsic discount16 Aug
US$9.51
1Y
62.6%7D
8.6%